Ambrisentan

Active ingredient: Ambrisentan

In short: Ambrisentan tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in adult patients: To improve exercise ability and delay clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II–III symptoms and eti

Forms & strengths5 mg and 10 mg film -coated tablets for oral administration Each 5 mg tablet is pale pink, biconvex, beveled edged, arc square film-coated tablet. Engraved "APO" on one side, "A5" on the other side. …
LabelGolden State Medical Supply, Inc.
Label updatedOct 21, 2026

What is Ambrisentan used for?

Ambrisentan tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in adult patients:

To improve exercise ability and delay clinical worsening.

Studies establishing effectiveness included predominantly patients with WHO Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%).

⚠ Boxed warning (FDA's strongest warning)

Ambrisentan tablets are contraindicat

ed for use during pregnancy because it may cause major birth defects if used by pregnant patients, based on studies in animals [see Contraindications (4.1), Warnings and Precautions (5.1), and Use in Specific Populations (8.1)].

Therefore, for females of reproductive potential, exclude pregnancy before the initiation of treatment must use acceptable methods of contraception during treatment with ambrisentan tablets. Advise use of effective contraception before initiation, during treatment, and for one

month after treatment with ambrisentan tablets

[see Dosage and Administration (2.2), Contraindications (4.1), Warnings and Precautions (5.1), and Use in Specific Populations (8.1, 8.3)].

When pregnancy is detected, discontinue ambrisentan tablets as soon as possible (5.1).

Ambrisentan dosage

Initiate treatment at 5 mg once daily. At 4-week intervals, the dose of ambrisentan can be increased, as needed and tolerated, to ambrisentan 10 mg.

Do not split, crush, or chew tablets.

Exclude pregnancy before initiating treatment with ambrisentan tablets in females of reproductive potential

.

How to take Ambrisentan — instructions & advice from the label

Advise patients to read the FDA-approved patient labeling (Medication Guide).

Instruct patients on the risk of fetal harm when ambrisentan tablets are used in pregnancy

.

Instruct females of reproductive potential to immediately contact their physician if they suspect they may be pregnant. Educate and counsel patients who can become pregnant about the need to use effective contraception prior to treatment with ambrisentan tablets, during treatment, and for one month after treatment discontinuation

.Patients who can become pregnant should have a negative pregnancy test prior to treatment with ambrisentan tablets

[see Dosage and Administration (2.2), Contraindications (4.1), Warnings and Precautions (5.1), Use in Specific Populations (8.1, 8.3)].

Counsel patients who can become pregnant about pregnancy planning and prevention, including emergency contraception, or designate counseling by another healthcare provider trained in contraceptive counseling

.

Hepatic Effects

Advise patients of the symptoms of potential liver injury and instruct them to report any of these symptoms to their physician.

Hematological Change

Advise patients of the importance of hemoglobin testing. …

Warnings & precautions

Do not take this medicine if: Ambrisentan tablets may cause fetal harm when administered to a pregnant female. Ambrisentan tablets are contraindicated in females who are pregnant. Ambrisentan was consistently shown to have teratogenic effects when administered to animals. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus

[see Dosage and Administration (2.2), Warnings and Precautions (5.1), and Use in Specific Populations (8.1)].

Ambrisentan tablets are contraindicated in patients with Idiopathic Pulmonary Fibrosis (IPF), including IPF patients with pulmonary hypertension (WHO Group 3)

.

Based on data from animal reproduction studies, ambrisentan tablets may cause fetal harm when administered during pregnancy and is contraindicated during pregnancy. The available human data for endothelin receptor antagonists do not establish the presence or absence of major birth defects related to the use of ambrisentan tablets. Advise patients who can become pregnant of the potential risk to a fetus. Obtain a pregnancy test prior to initiation of treatment with ambrisentan tablets. Advise patients who can become pregnant to use effective contraception prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with ambrisentan tablets. When pregnancy is detected, discontinue use as soon as possible

.

Peripheral edema is a known class effect of endothelin receptor antagonists, and is also a clinical consequence of PAH and worsening PAH. In the placebo-controlled studies, there was an increased incidence of peripheral edema in patients treated with doses of 5 or 10 mg ambrisentan tablets compared to placebo

. Most edema was mild to moderate in severity. …

Ambrisentan side effects

Clinically significant adverse reactions that appear in other sections of the labeling include:

Embryo-fetal Toxicity

Fluid Retention

Pulmonary Edema with PVOD

Decreased Sperm Count

Hematologic Changes

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Safety data for ambrisentan tablets are presented from two 12-week, placebo-controlled studies (ARIES-1 and ARIES-2) in patients with pulmonary arterial hypertension (PAH). The exposure to ambrisentan in these studies ranged from 6 days to 100 days.

In ARIES-1 and ARIES-2, a total of 261 patients received ambrisentan tablets at doses of 2.5 mg, 5 mg, or 10 mg once daily and 132 patients received placebo. The adverse reactions that occurred in >3% more patients receiving ambrisentan tablets than receiving placebo are shown in Table 1.

Placebo

(N=132) | Ambrisentan tablets

(N=261)

Adverse Reaction | n (%) | n (%) | Placebo-adjusted (%)

Peripheral edema | 14 (11) | 45 (17) | 6

Nasal congestion | 2 (2) | 15 (6) | 4

Sinusitis | 0 (0) | 8 (3) | 3

Flushing | 1 (1) | 10 (4) | 3

Most adverse drug reactions were mild to moderate and only nasal congestion was dose-dependent.

Few notable differences in the incidence of adverse reactions were observed for patients by age or sex. …

Drug interactions

Multiple dose coadministration of ambrisentan and cyclosporine resulted in an approximately 2 fold increase in ambrisentan exposure in healthy volunteers; therefore, limit the dose of ambrisentan to 5 mg once daily when coadministered with cyclosporine

.

About this medicine

Ambrisentan, is an endothelin receptor antagonist. The chemical name of ambrisentan is (+)-(2

S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid. It has a molecular formula of C

22H

22N

2O

4and a molecular weight of 378.42 g/mol and has the following structural formula:

Figure 1 Ambrisentan Structural Formula

Ambrisentan is a white to yellow powder. It is a carboxylic acid with a pKa of 4.0. Ambrisentan is freely soluble in THF, sparingly soluble in ethyl acetate, slightly soluble in ethanol, practically insoluble in n-hexane and water. Ambrisentan is not hygroscopic.

Ambrisentan tablets are available as 5 mg and 10 mg film-coated tablets for once daily oral administration. The tablets include the following inactive ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate and microcrystalline cellulose. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 4396bab5-2851-62ef-e063-6294a90af76e. Read the full official label on DailyMed.

Related medicines

Amlodipine Lisinopril Metoprolol Hydrochlorothiazide Tamsulosin Carvedilol Potassium Chloride Spironolactone